We read with interest the recently published paper by Werner et al. on the impact of prostate cancer tumor burden on uptake of [18F] DCFPyL, a 2nd-generation fluorine-labeled prostate-specific membrane antigen (PSMA) ligand, in normal tissues [1]. Such studies are essential for future use of theranostic PSMA radioligand therapies (eg,[177Lu] PMSA), as the presence of a so-called sink effect might require adaptation of therapeutic dosages to intrapatient tumor volumes. The authors performed a secondary analysis on a cohort of 50 prostate cancer patients that underwent [18F] DCFPyL positron emission tomography/computer tomography (PET/CT) for various clinical indications, correlating PSMA-positive tumor volume with uptake values in normal tissues. They concluded that, in their cohort, PSMA-positive tumor volume did not correlate with [18F] DCFPyL uptake in normal organs, such as lacrimal glands, parotid glands, submandibular glands, spleen, and liver. Of all tissues examined, only the left kidney uptake correlated significantly with tumor volume. We would like to compliment the authors for their thorough analysis and appropriate acknowledgment of its limitations. In this reply, we would like to address some additional methodologic aspects and supplement the analysis of Werner et al. with our own experience of [18F] DCFPyL imaging, especially those patients with larger tumor volumes.